207 related articles for article (PubMed ID: 17210670)
1. A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesis.
Hancock AL; Brown KW; Moorwood K; Moon H; Holmgren C; Mardikar SH; Dallosso AR; Klenova E; Loukinov D; Ohlsson R; Lobanenkov VV; Malik K
Hum Mol Genet; 2007 Feb; 16(3):343-54. PubMed ID: 17210670
[TBL] [Abstract][Full Text] [Related]
2. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
[TBL] [Abstract][Full Text] [Related]
3. Identification of differential methylation of the WT1 antisense regulatory region and relaxation of imprinting in Wilms' tumor.
Malik K; Salpekar A; Hancock A; Moorwood K; Jackson S; Charles A; Brown KW
Cancer Res; 2000 May; 60(9):2356-60. PubMed ID: 10811108
[TBL] [Abstract][Full Text] [Related]
4. Frequent hypermethylation of a CTCF binding site influences Wilms tumor 1 expression in Wilms tumors.
Zitzmann F; Mayr D; Berger M; Stehr M; von Schweinitz D; Kappler R; Hubertus J
Oncol Rep; 2014 Apr; 31(4):1871-6. PubMed ID: 24534946
[TBL] [Abstract][Full Text] [Related]
5. Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer.
Wagner KJ; Cooper WN; Grundy RG; Caldwell G; Jones C; Wadey RB; Morton D; Schofield PN; Reik W; Latif F; Maher ER
Oncogene; 2002 Oct; 21(47):7277-82. PubMed ID: 12370819
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
[TBL] [Abstract][Full Text] [Related]
7. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
8. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
9. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors.
Iben S; Royer-Pokora B
Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205
[TBL] [Abstract][Full Text] [Related]
10. Identical genetic changes in different histologic components of Wilms' tumors.
Zhuang Z; Merino MJ; Vortmeyer AO; Bryant B; Lash AE; Wang C; Deavers MT; Shelton WF; Kapur S; Chandra RS
J Natl Cancer Inst; 1997 Aug; 89(15):1148-52. PubMed ID: 9262253
[TBL] [Abstract][Full Text] [Related]
11. Wilms' tumor gene 1: lessons from the interface between kidney development and cancer.
Torban E; Goodyer P
Am J Physiol Renal Physiol; 2024 Jan; 326(1):F3-F19. PubMed ID: 37916284
[TBL] [Abstract][Full Text] [Related]
12. Cell types expressing the Wilms' tumour gene (WT1) in Wilms' tumours: implications for tumour histogenesis.
Pritchard-Jones K; Fleming S
Oncogene; 1991 Dec; 6(12):2211-20. PubMed ID: 1722569
[TBL] [Abstract][Full Text] [Related]
13. Loss of imprinting of insulin-like growth factor-II in Wilms' tumor commonly involves altered methylation but not mutations of CTCF or its binding site.
Cui H; Niemitz EL; Ravenel JD; Onyango P; Brandenburg SA; Lobanenkov VV; Feinberg AP
Cancer Res; 2001 Jul; 61(13):4947-50. PubMed ID: 11431321
[TBL] [Abstract][Full Text] [Related]
14. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells.
Fu VX; Schwarze SR; Kenowski ML; Leblanc S; Svaren J; Jarrard DF
J Biol Chem; 2004 Dec; 279(50):52218-26. PubMed ID: 15471867
[TBL] [Abstract][Full Text] [Related]
15. Rasgrf1 imprinting is regulated by a CTCF-dependent methylation-sensitive enhancer blocker.
Yoon B; Herman H; Hu B; Park YJ; Lindroth A; Bell A; West AG; Chang Y; Stablewski A; Piel JC; Loukinov DI; Lobanenkov VV; Soloway PD
Mol Cell Biol; 2005 Dec; 25(24):11184-90. PubMed ID: 16314537
[TBL] [Abstract][Full Text] [Related]
16. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
Ramani P; Cowell JK
J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
[TBL] [Abstract][Full Text] [Related]
17. A developmental context for multiple genetic alterations in Wilms' tumor.
Feinberg AP
J Cell Sci Suppl; 1994; 18():7-12. PubMed ID: 7883796
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumour: reconciling genetics and biology.
Van Heyningen V; Hastie ND
Trends Genet; 1992 Jan; 8(1):16-21. PubMed ID: 1369730
[TBL] [Abstract][Full Text] [Related]
19. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms causing imprinting defects in familial Beckwith-Wiedemann syndrome with Wilms' tumour.
Sparago A; Russo S; Cerrato F; Ferraiuolo S; Castorina P; Selicorni A; Schwienbacher C; Negrini M; Ferrero GB; Silengo MC; Anichini C; Larizza L; Riccio A
Hum Mol Genet; 2007 Feb; 16(3):254-64. PubMed ID: 17158821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
